Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 114.59 -2.14% -2.51
ALXN closed down 2.14 percent on Thursday, February 22, 2018, on 68 percent of normal volume.
2 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ALXN trend table...

Date Alert Name Type % Chg
Feb 22 Wide Bands Range Expansion 0.00%
Feb 22 Down 3 Days in a Row Weakness 0.00%
Feb 22 Down 4 Days in a Row Weakness 0.00%
Feb 22 Down 5 Days in a Row Weakness 0.00%
Feb 21 50 DMA Resistance Bearish -2.14%
Feb 21 Multiple of Ten Bearish Other -2.14%
Feb 21 Wide Bands Range Expansion -2.14%
Feb 21 Down 3 Days in a Row Weakness -2.14%
Feb 21 Down 4 Days in a Row Weakness -2.14%
Feb 20 Fell Below 50 DMA Bearish -3.58%

Older signals for ALXN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Is ALXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 149.34
52 Week Low 96.18
Average Volume 1,950,886
200-Day Moving Average 124.2676
50-Day Moving Average 119.2554
20-Day Moving Average 118.196
10-Day Moving Average 116.339
Average True Range 4.5507
ADX 19.19
+DI 24.54
-DI 28.25
Chandelier Exit (Long, 3 ATRs ) 115.4979
Chandelier Exit (Short, 3 ATRs ) 118.6021
Upper Bollinger Band 128.7738
Lower Bollinger Band 107.6182
Percent B (%b) 0.33
BandWidth 17.898744
MACD Line -0.7497
MACD Signal Line -0.7996
MACD Histogram 0.0499
Fundamentals Value
Market Cap 25.58 Billion
Num Shares 223 Million
EPS 2.31
Price-to-Earnings (P/E) Ratio 49.61
Price-to-Sales 8.25
Price-to-Book 3.18
PEG Ratio 1.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 120.85
Resistance 3 (R3) 121.37 119.82 119.80
Resistance 2 (R2) 119.82 118.22 119.55 119.45
Resistance 1 (R1) 117.20 117.24 116.43 116.68 119.11
Pivot Point 115.65 115.65 115.26 115.38 115.65
Support 1 (S1) 113.03 114.05 112.26 112.51 110.07
Support 2 (S2) 111.48 113.07 111.21 109.73
Support 3 (S3) 108.86 111.48 109.38
Support 4 (S4) 108.34